About Bacchus Vascular
Bacchus Vascular is a Healthcare company based in Santa Clara (United States) founded in 1999, and was acquired by Covidien in March 2009. Devices for treatment of vascular disease. Bacchus Vascular has raised $31.5 million across 2 funding rounds from investors including Warburg Pincus, Covidien and Kaiser Permanente Ventures. The company was acqui-hired. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Tactile Medical, enVVeno Medical and DeVoro Medical; 2 of its 3 listed competitors have raised funding.
Company details
Bacchus Vascular was focused on medical devices for the treatment of occlusive vascular disease for interventional radiologists and vascular surgeons in the United States. Its product, the TRELLIS-8 Peripheral Infusion System is an isolated thrombolysis catheter that enables treatment of deep vein thrombosis and arterial occlusions by targeted delivery of clot-dissolving drugs. The company was founded in 1999 and is based in Santa Clara, California. It was acquired by Covidien in 2009 which in turn was acquired by Medtronic in 2015.
- Headquarters Santa Clara, United States
- Stage Acquired
- SectorsHealthcare
- Website bacchus-vascular.com
- Social LinkedIn
- Acquired by Covidien (Mar 2009)
- Total Equity Funding$31.5M (USD)
in 2 rounds
- Latest Funding Round$6.5M (USD), Series E
Apr 2007
- InvestorsWarburg Pincus
& 3 more
- Acquired byCovidien
(Mar 2009)
Funding Insights of Bacchus Vascular
Bacchus Vascular has successfully raised a total of $31.5M across 2 strategic funding rounds. The most recent funding activity was a Series E round of $6.5 million completed in April 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $31.5M
- Total Rounds 2
- Last Round Series E — $6.5M
- First Round $25M
(Jul 2003)
- Investors Count 3
All 2 funding rounds of Bacchus Vascular with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2007 | $6.5M | Series E | – | – | |
| Jul 2003 | $25M | Series D | – | – |
4 investors in total: 4 institutional.
Investors in Bacchus Vascular
Bacchus Vascular has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Warburg Pincus, Covidien and Kaiser Permanente Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-stage private equity investments are pursued across diverse sectors. | 1966 | warburgpincus.com | New York, United States | |
Tech and Life Sciences focused corporate VC firm investing in the US | kpventures.com | Oakland, United States | ||
Investments in early and late-stage US companies are made. | vertical-group.com | Basking Ridge, United States | ||
Medical devices for minimally invasive therapies are provided globally. | 2007 | covidien.com | Dublin, Ireland |
Investor details for Bacchus Vascular
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Bacchus Vascular
4 dated milestones of Bacchus Vascular across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Bacchus Vascular is founded.
- Funding First funding round of $25.0M.
- Funding Latest funding round, Series E, of $6.5M.
- Exit Acquired by Covidien.
Competitors of Bacchus Vascular
Bacchus Vascular has 3 listed competitors in our database, 2 of them funded. They include Tactile Medical, enVVeno Medical and DeVoro Medical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tactilemedical.com | 1995 | Minneapolis, United States | $23.2M | 592 | Home therapy devices for lymphedema and venous ulcers are provided. | |
| envveno.com | 1999 | Irvine, United States | 31 | Developer of medical device for the the treatment of venous diseases | ||
| devoromedical.com | 2018 | Fremont, United States | $18M | Medical devices for treating cardiac diseases are developed. |
Detailed competitors of Bacchus Vascular
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bacchus Vascular
Websites that share an audience with Bacchus Vascular (bacchus-vascular.com).
Websites whose visitors overlap most with Bacchus Vascular. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| facebook.com | 100% | 12.1B | #3 | View details |
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Bacchus Vascular (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bacchus Vascular
Complete news archive for Bacchus Vascular
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bacchus Vascular
Bacchus Vascular was founded in 1999 and raised its 1st funding round 4 years after it was founded.
Bacchus Vascular is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Bacchus Vascular is a funded company, having raised a total of $31.5M across 2 funding rounds to date. The company's 1st funding round was a Series D of $25M, raised on Jul 2003.
Bacchus Vascular was focused on medical devices for the treatment of occlusive vascular disease for interventional radiologists and vascular surgeons in the United States. Its product, the TRELLIS-8 Peripheral Infusion System is an isolated thrombolysis catheter that enables treatment of deep vein thrombosis and arterial occlusions by targeted delivery of clot-dissolving drugs. The company was founded in 1999 and is based in Santa Clara, California. It was acquired by Covidien in 2009 which in turn was acquired by Medtronic in 2015.
Bacchus Vascular's top competitors include Tactile Medical, enVVeno Medical and DeVoro Medical.
Bacchus Vascular has 4 investors. Key investors include Warburg Pincus, Covidien, Kaiser Permanente Ventures, and The Vertical Group.
Yes. Bacchus Vascular was acquired by Covidien in March 2009.